Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | F10 | P00742 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4711774 | 0.91 | MAPT (0.51) | MAPTKDM4ETDP1NPSR1MAPK1 | |
| SCHEMBL4714035 | 0.89 | CCR2 (0.48) | — | |
| SCHEMBL4716102 | 0.88 | MAPT (0.57) | MAPTKDM4ETDP1NPSR1MAPK1 | |
| SCHEMBL4715856 | 0.87 | CCR2 (0.40) | KDM4EALDH1A1HSD17B10F10GAA | |
| SCHEMBL4712174 | 0.85 | MAPT (0.51) | MAPTKDM4ETDP1NPSR1MAPK1 | |
| SCHEMBL4789434 | 0.85 | ALDH1A1 (0.53) | MAPTKDM4ETDP1NPSR1MAPK1 | |
| Phenylboronic Acid SCHEMBL6530013 | 0.82 | MAPT (0.51) | MAPTKDM4ETDP1NPSR1MAPK1 | |
| SCHEMBL4716291 | 0.79 | NOD2 (0.52) | MAPTKDM4ETDP1NPSR1MAPK1 | |
| SCHEMBL4789540 | 0.77 | MAPT (0.49) | MAPTKDM4ETDP1NPSR1MAPK1 | |
| SCHEMBL4714560 | 0.77 | CCR2 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456286-B2 | Bicyclic heteroaromatic compounds as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2008-11-25 | — | — | US | claimed |
| US-20060122212-A1 | Bicyclic heteroaromatic compounds as kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2006-06-08 | — | — | US | claimed |
| US-7456286-B2 | Bicyclic heteroaromatic compounds as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2008-11-25 | — | — | US | disclosed |
| EP-1549648-B1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2008-11-12 | — | — | EP | disclosed |
| US-20060122212-A1 | Bicyclic heteroaromatic compounds as kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2006-06-08 | — | — | US | disclosed |
| EP-1549648-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS | Celltech R & D Limited (GB) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004031188-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS | CELLTECH R & D LIMITED (GB) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122212-A1 | Bicyclic heteroaromatic compounds as kinase inhibitors | MAP2K2, MAP2K7, MAP2K3 | MAPT 1831/4885KDM4E 2030/4885TDP1 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.